Physician profile
Kendrick Thomas
NPI 1528383965
$4,204.87
in general payments reported to CMS, 2019-2025
20 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $143 · 2021: $1,186 · 2022: $640 · 2023: $724 · 2024: $947 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,572.29 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Intracept |
| Medtronic, INC. | $1,329.70 | 2021-2024 | Intellis Adaptivestim |
| Nalu Medical, INC. | $442.91 | 2023-2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.75 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $119.61 | 2021-2024 | |
| Stryker Corporation | $97.92 | 2021-2025 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $94.93 | 2024-2025 | Xtampza |
| Abbvie INC. | $88.43 | 2021-2023 | Qulipta |
| Vertex Pharmaceuticals Incorporated | $67.15 | 2024-2025 | |
| Spr Therapeutics, INC | $57.82 | 2022-2024 | Sprint Pns System |
| Valinor Pharma, LLC | $38.10 | 2025 | Movantik |
| Anika Therapeutics, INC. | $32.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.00 | 2022 | |
| Amgen INC. | $18.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $14.13 | 2021 | |
| Lundbeck LLC | $13.43 | 2022 | |
| Radius Health, INC. | $11.75 | 2022 | |
| Organogenesis INC. | $11.27 | 2021 | |
| Grt US Holding, INC. | $8.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendrick Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.